A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II): Effects of variations of the OMV and protein content on immunogenicity and reactogenicity

The licensed meningococcal serogroup B vaccine, 4CMenB (Bexsero(®)), contains recombinant membrane proteins (rMenB) and outer membrane vesicles (OMV) of the New Zealand serogroup B strain. We investigated whether reducing the OMV and/or protein content influences 4CMenB immunogenicity and reactogeni...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Esposito, Susanna, Prymula, Roman, Zuccotti, Gian Vincenzo, Xie, Fang, Barone, Michelangelo, Dull, Peter M, Toneatto, Daniela
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186018/
https://ncbi.nlm.nih.gov/pubmed/25424810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.29218
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados